IRON · Insider Trading
Disc Medicine, Inc. Common Stock
Every open-market purchase and sale reported by IRON officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | John D Quisel | Chief Executive Officer | M | +36,000 | +$36.36K |
| 2026-09-15 | Kevin Bitterman | Director | MIXED | — | −$679.36K |
| 2026-09-09 | Kevin Bitterman | Director | Sell | −1,689 | −$135.05K |
| 2026-09-03 | Kevin Bitterman | Director | Sell | −54,496 | −$4.37M |
| 2026-08-26 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$633.06K |
| 2026-08-18 | John D Quisel | Chief Executive Officer | MIXED | — | −$2.17M |
| 2026-08-14 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$55.59K |
| 2026-08-07 | Rahul Khara | Chief Legal Officer | MIXED | — | −$326.55K |
| 2026-08-07 | Rahul Khara | Chief Legal Officer | MIXED | — | −$326.55K |
| 2026-07-14 | John D Quisel | Chief Executive Officer | MIXED | — | −$2.12M |
| 2026-07-09 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$6.90K |
| 2026-06-24 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$573.85K |
| 2026-06-23 | Kevin Bitterman | Director | A | +6,212 deriv. | — |
| 2026-06-23 | Liam Ratcliffe | Director | A | +6,212 deriv. | — |
| 2026-06-23 | William Richard White | Director | A | +6,212 deriv. | — |
| 2026-06-23 | Nadim Ahmed | Director | A | +5,176 deriv. | — |
| 2026-06-23 | Georges Gemayel | Director | A | +6,212 deriv. | — |
| 2026-06-23 | Donald William Nicholson | Director | A | +6,212 deriv. | — |
| 2026-06-23 | Mark Chin | Director | A | +6,212 deriv. | — |
| 2026-06-23 | Rahul Khara | Chief Legal Officer | MIXED | — | −$416.49K |
| 2026-06-23 | John D Quisel | Chief Executive Officer | MIXED | — | −$2.05M |
| 2026-06-18 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$1.10M |
| 2026-04-15 | William Jacob Savage | Chief Medical Officer | Sell | −5,731 | −$380.45K |
| 2026-04-15 | Jean M. Franchi | Chief Financial Officer | Sell | −6,657 | −$460.83K |
| 2026-03-04 | William Jacob Savage | Chief Medical Officer | Sell | −7,378 | −$486.07K |
| 2026-02-27 | Jean M. Franchi | Chief Financial Officer | Sell | −353 | −$24.38K |
| 2026-02-19 | Jean M. Franchi | Chief Financial Officer | Sell | −11,156 | −$719.73K |
| 2026-02-17 | Rahul Khara | Chief Legal Officer | Sell | −2,853 | −$179.34K |
| 2026-02-17 | William Jacob Savage | Chief Medical Officer | Sell | −3,256 | −$204.67K |
| 2026-02-17 | John D Quisel | Chief Executive Officer | Sell | −13,264 | −$833.78K |
| 2026-02-17 | Pamela Stephenson | Chief Commercial Officer | Sell | −5,531 | −$347.68K |
| 2026-02-17 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sell | −3,231 | −$203.10K |
| 2026-02-11 | William Jacob Savage | Chief Medical Officer | A | +17,000 | — |
| 2026-02-11 | Pamela Stephenson | Chief Commercial Officer | A | +17,000 | — |
| 2026-02-11 | Rahul Khara | Chief Legal Officer | A | +17,000 | — |
| 2026-02-11 | Jean M. Franchi | Chief Financial Officer | A | +19,000 | — |
| 2026-02-11 | Jonathan Yen-Wen Yu | Chief Operating Officer | A | +17,000 | — |
| 2026-02-11 | John D Quisel | Chief Executive Officer | A | +55,200 | — |
| 2026-01-21 | Rahul Khara | Chief Legal Officer | MIXED | — | −$56.24K |
| 2026-01-05 | Rahul Khara | Chief Legal Officer | MIXED | — | −$423.72K |
| 2025-12-29 | William Jacob Savage | Chief Medical Officer | M | +3,143 | +$31.35K |
| 2025-12-19 | John D Quisel | Chief Executive Officer | M | +12,300 | +$12.42K |
| 2025-12-18 | Kevin Bitterman | Director | Sell | −754 | −$68.97K |
| 2025-12-16 | William Jacob Savage | Chief Medical Officer | Sell | −13,093 | −$1.19M |
| 2025-12-16 | Kevin Bitterman | Director | MIXED | −177,123 | −$16.76M |
| 2025-12-15 | John D Quisel | Chief Executive Officer | MIXED | — | −$3.33M |
| 2025-11-13 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | −$2.46M |
| 2025-10-24 | Access Industries Holdings LLC | 10%+ Owner | Sell | −2,976,188 | −$239.49M |
| 2025-10-17 | Kevin Bitterman | Director | Sell | −93,585 | −$8.05M |
| 2025-10-09 | Kevin Bitterman | Director | Sell | −90,000 | −$6.31M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Access Industries Holdings LLC | 10%+ Owner | 2,814,379 | $222.14M |
| OrbiMed Capital GP VI LLC | Director | 776,844 | $61.32M |
| OrbiMed Genesis GP LLC | Director | 746,171 | $58.90M |
| Mona Ashiya | Director | 484,032 | $38.20M |
| Kevin Bitterman | Director | 336,002 | $26.52M |
| John D Quisel | Chief Executive Officer | 262,064 | $20.68M |
| Pamela Stephenson | Chief Commercial Officer | 80,998 | $6.39M |
| William Jacob Savage | Chief Medical Officer | 79,480 | $6.27M |
| Jean M. Franchi | Chief Financial Officer | 70,590 | $5.57M |
| Rahul Khara | Chief Legal Officer | 57,324 | $4.52M |
| Jonathan Yen-Wen Yu | Chief Operating Officer | 54,624 | $4.31M |
| William Richard White | Director | 1,756 | $138.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IRON quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.